Afrooz Rashnonejad

Dr. Afrooz Rashnonejad


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2018 in JCI Insight
Verified
Journal Article
Closed access
PDF file
CGCarlee R. Giesige
Carlee R. Giesige
LWLindsay M. Wallace
Lindsay M. Wallace
KHKristin N. Heller
Kristin N. Heller
JEJocelyn O. Eidahl
Jocelyn O. Eidahl
NSNizar Y. Saad
Nizar Y. Saad
SHScott Q. Harper
Scott Q. Harper
Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal dominant or digenic disorder linked to derepression of the toxic DUX4 gene in muscle. There is currently no pharmacological treatment. The emergence of DUX4 enabled development of cell and animal models that could be used for basic and translational research. Since DUX4 is toxic, animal model development has been challenging, but progress has been made, revealing that tight regulation of DUX4 expression is critical for creating viable animals that develop myopathy. Here, we report such a model — the tamoxifen-inducible FSHD mouse model called TIC-DUX4. Uninduced animals are viable, born in Mendelian ratios, and overtly indistinguishable from WT animals. Induced animals display significant DUX4-dependent myopathic phenotypes at the molecular, histological, and functional levels. To demonstrate the utility of TIC-DUX4 mice for therapeutic development, we tested a gene therapy approach aimed at improving muscle strength in DUX4-expressing muscles using adeno-associated virus serotype 1.Follistatin (AAV1.Follistatin), a natural myostatin antagonist. This strategy was not designed to modulate DUX4 but could offer a mechanism to improve muscle weakness caused by DUX4-induced damage. AAV1.Follistatin significantly increased TIC-DUX4 muscle mass and strength even in the presence of DUX4 expression, suggesting that myostatin inhibition may be a promising approach to treat FSHD-associated weakness. We conclude that TIC-DUX4 mice are a relevant model to study DUX4 toxicity and, importantly, are useful in therapeutic development studies for FSHD.

1 December 2019 in Molecular Therapy
Verified
Journal Article
Open access
ARAfrooz Rashnonejad
Afrooz Rashnonejad
GCGholamhossein Amini Chermahini
Gholamhossein Amini Chermahini
CGCumhur Gündüz
Cumhur Gündüz
HOHüseyin Onay
Hüseyin Onay
AAAyça Aykut
Ayça Aykut
FÖFerda Özkınay
Ferda Özkınay
Symptoms of spinal muscular atrophy (SMA) disease typically begin in the late prenatal or the early postnatal period of life. The intrauterine (IU) correction of gene expression, fetal gene therapy, could offer effective gene therapy approach for early onset diseases. Hence, the overall goal of this study was to investigate the efficacy of human survival motor neuron (hSMN) gene expression after IU delivery in SMA mouse embryos. First, we found that IU-intracerebroventricular (i.c.v.) injection of adeno-associated virus serotype-9 (AAV9)-EGFP led to extensive expression of EGFP protein in different parts of the CNS with a great number of transduced neural stem cells. Then, to implement the fetal gene therapy, mouse fetuses received a single i.c.v. injection of a single-stranded (ss) or self-complementary (sc) AAV9-SMN vector that led to a lifespan of 93 (median of 63) or 171 (median 105) days for SMA mice. The muscle pathology and number of the motor neurons also improved in both study groups, with slightly better results coming from scAAV treatment. Consequently, fetal gene therapy may provide an alternative therapeutic approach for treating inherited diseases such as SMA that lead to prenatal death or lifelong irreversible damage.

25 November 2015 in Molecular Biotechnology
Verified
Journal Article
Closed access
PDF file
ARAfrooz Rashnonejad
Afrooz Rashnonejad
GCGholamhossein Amini Chermahini
Gholamhossein Amini Chermahini
SLShaoyong Li
Shaoyong Li
FOFerda Ozkinay
Ferda Ozkinay
GGGuangping Gao
Guangping Gao

16 February 2018 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
ARAfrooz Rashnonejad
Afrooz Rashnonejad
GEGulinnaz Ercan
Gulinnaz Ercan
CGCumhur Gunduz
Cumhur Gunduz
AAAli Akdemir
Ali Akdemir
YTYigit Ozer Tiftikcioglu
Yigit Ozer Tiftikcioglu

1 March 2012
Verified
Journal Article
Open access
JNJamileh Nowroozi
Jamileh Nowroozi
ASAbbas Akhavan Sepahi
Abbas Akhavan Sepahi
ARAfrooz Rashnonejad
Afrooz Rashnonejad
Objective: Pyocyanine plays an important role in the pathogenesis of Pseudomonas aeruginosa, (P aeruginosa) and is known to have inhibitory and bactericidal effects. This study has aimed to detect the phenazine biosynthetic operon (phz ABCDEFG) and two phenazine modifying genes (phzM and phzS) by polymerase chain reaction (PCR) and detection of its possible protein bands by sodium dodecyl sulfate - polyacrylamide gel electrophoresis (SDS-PAGE). The antimicrobial effects of pyocyanine alone and mixed with colloidal silver nanoparticles were studied. Materials and Methods: In this descriptive study, clinical and environmental species of P. aeruginosa were isolated by thioglycollate medium culture and cetrimide agar, respectively. The existence of a phenazine biosynthetic operon and two phenazine modifying genes as well as their protein products were confirmed by PCR and SDS-PAGE, respectively. Pyocyanine was extracted with chloroform and its antimicrobial effects against bacteria such as; Escherichia coli (E. coli), P aeruginosaand Staphylococcus aureus (S. aureus) bacteria and yeast Candida albicans (C. albicans) were tested using well, spot and disk diffusion methods. Results: In this study, 3 out of 48 clinical strains were unable to produce pyocyanine on cetrimide and Mueller Hinton (MH) agar. Two strains did not have phenazine modifying gene bands. Another strain did not have the possible protein band of the phzM gene. Pyocyanine had antimicrobial effects against the microbial strains, which increased in the presence of silver nanoparticles. Conclusion: According to the results of the present study, some P aeruginosa strains are unable to produce pyocyanine due to the absence of the phzM or phzS genes. Therefore, these genes have an important role in pyocyanine production in P aeruginosa. Pyocyanine shows synergistic antimicrobial effects in the presence of silver nanoparticles against microbial strains.

Verified
Journal Article
Open access
PDF file
MMMary Kate McCulloch
Mary Kate McCulloch
FMFatemeh Mehryab
Fatemeh Mehryab
ARAfrooz Rashnonejad
Afrooz Rashnonejad
Charcot–Marie–Tooth type 1B (CMT1B) is a peripheral neuropathy caused by mutations in the gene encoding myelin protein zero (MPZ), a key component of the myelin sheath in Schwann cells. Mutations in the MPZ gene can lead to protein misfolding, unfolded protein response (UPR), endoplasmic reticulum (ER) stress, or protein mistrafficking. Despite significant progress in understanding the disease mechanisms, there is currently no effective treatment for CMT1B, with therapeutic strategies primarily focused on supportive care. Gene therapy represents a promising therapeutic approach for treating CMT1B. To develop a treatment and better design preclinical studies, an in-depth understanding of the pathophysiological mechanisms and animal models is essential. In this review, we present a comprehensive overview of the disease mechanisms, preclinical models, and recent advancements in therapeutic research for CMT1B, while also addressing the existing challenges in the field. This review aims to deepen the understanding of CMT1B and to encourage further research towards the development of effective treatments for CMT1B patients.